AR114444A1 - SEQUENCING METHOD FOR T-CELL THERAPY WITH CAR - Google Patents

SEQUENCING METHOD FOR T-CELL THERAPY WITH CAR

Info

Publication number
AR114444A1
AR114444A1 ARP190100445A ARP190100445A AR114444A1 AR 114444 A1 AR114444 A1 AR 114444A1 AR P190100445 A ARP190100445 A AR P190100445A AR P190100445 A ARP190100445 A AR P190100445A AR 114444 A1 AR114444 A1 AR 114444A1
Authority
AR
Argentina
Prior art keywords
car
cell therapy
sequencing method
patient
administering
Prior art date
Application number
ARP190100445A
Other languages
Spanish (es)
Inventor
Julie Ruggieri Park
Navin Robert Charles Pinto
James Matthaei
Michael C Jensen
Philip S Low
Yingjuan J Lu
Haiyan Chu
Christopher P Leamon
Richard Messmann
Original Assignee
Endocyte Inc
Purdue Research Foundation
Seattle Children’S Hospital Dba Seattle Children’S Res Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc, Purdue Research Foundation, Seattle Children’S Hospital Dba Seattle Children’S Res Institute filed Critical Endocyte Inc
Publication of AR114444A1 publication Critical patent/AR114444A1/en

Links

Abstract

La presente divulgación se refiere a métodos para tratar un paciente con cáncer mediante la administración al paciente de una composición que comprende células T con CAR y administrar al paciente una pequeña molécula ligada a una fracción del receptor mediante un conector. La presente divulgación asimismo se refiere a composiciones para su uso en dichos métodos.The present disclosure relates to methods of treating a cancer patient by administering to the patient a composition comprising CAR T cells and administering to the patient a small molecule linked to a fraction of the receptor via a linker. The present disclosure also relates to compositions for use in such methods.

ARP190100445A 2018-02-23 2019-02-22 SEQUENCING METHOD FOR T-CELL THERAPY WITH CAR AR114444A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862634573P 2018-02-23 2018-02-23

Publications (1)

Publication Number Publication Date
AR114444A1 true AR114444A1 (en) 2020-09-09

Family

ID=72670896

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100445A AR114444A1 (en) 2018-02-23 2019-02-22 SEQUENCING METHOD FOR T-CELL THERAPY WITH CAR

Country Status (1)

Country Link
AR (1) AR114444A1 (en)

Similar Documents

Publication Publication Date Title
BR112018070580A2 (en) methods and compositions for t cell therapy
CL2022003788A1 (en) Binding molecules against bcma and uses thereof
PH12019500436A1 (en) Adenovirus armed with bispecific t cell engager (bite)
BR112013003823A2 (en) therapeutic peptide-polymer conjugates, particles, compositions, and related methods
CO7350624A2 (en) Bruton tyrosine kinase inhibitors
CL2017002767A1 (en) New specific proteins for cd137.
BR112018067379A2 (en) antibody-drug conjugate, composition, method for treating a patient who has or is at risk of cancer, to produce the antibody-drug conjugate or composition, to determine if a patient will be responsive to treatment with the antibody-conjugate drug or composition, and use of an antibody-drug conjugate or composition.
CR20180027A (en) NEW PEPTIDES AND NEW COMBINATIONS OF PEPTIDES FOR USE IN THE SAME THERAPY AGAINST OVARY EPITELIAL CANCER AND OTHER TYPES OF CANCER.
CR20180074A (en) NEW PEPTIDES AND NEW COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER TYPES OF CANCER
BR112018070676A2 (en) multispecific antigen binding constructs that target immunotherapeutic agents
CY1119410T1 (en) OPTIMIZED monoclonal antibodies against the TFPI inhibitor (TFPI)
BRPI0905733B8 (en) composition, pharmaceutical formulation, method for producing a pharmaceutical composition and use of a pharmaceutical formulation
CO6351751A2 (en) HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
BR112014006176A8 (en) IN VITRO TRANSCRIBED RNA OR SYNTHETIC RNA, COMPOSITION, METHOD FOR GENERATING AN RNA GENETICALLY MODIFIED T CELL POPULATION, AND, USE OF A GENETICALLY MODIFIED T CELL
BR112013031892A2 (en) anti-psgl-1 antibodies and their use
CL2021000207A1 (en) New fusion proteins specific for cd137 and pd-l1
BR112016004108A2 (en) methods for expressing an antigenic molecule or a part thereof and for generating an immune response, pharmaceutical composition, cell or cell population, uses of a cell population and an antigenic molecule, antigenic molecules, photosensitizing agents and ligand tlr and agent product and kit
CR10143A (en) ANTIGENS OF DES-N-ACETYL-SIALIC ACID, ANTIBODIES FOR THE SAME AND METHODS OF USE IN CANCER THERAPY
PH12020550598A1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
BR112022008552A2 (en) N-TERMINAL SCFV MULTI-SPECIFIC BINDING MOLECULES
CL2008002545A1 (en) Phenoxy-benzyl-carbamoyl derived compounds; pharmaceutical composition; process for preparing the pharmaceutical composition; and its use in the treatment of pain.
DOP2009000208A (en) METHODS OF TREATMENT OF CANCER THROUGH ADMINISTRATION OF HUMAN IL-18 COMBINATIONS
BR112015031950A2 (en) Methods for Ovarian Cancer Treatment
AR115566A1 (en) COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF CANCER
UY35250A (en) ANTI-LAMP1 ANTIBODIES AND CONJUGATES ANTIBODY DRUG, AND USES OF THESE.